CASES DEATHS CASES DEATHS
December 2020 19,111,443 341,149 2,120,610 24,241
January 26,185,362 441,319 3,310,949 40,702
February 28,602,101 513,137 3,563,578 51,953
March 30,459,874 552,072 3,668,277 59,240
April 32,225,012 574,280 3,742,115 62,078
May 33,261,284 594,468 3,789,227 63,247
June 33,624,871 603,966 3,814,890 63,569
July 34,434,136 610,859 3,903,052 64,231
August 39,057,368 638,700 4,326,204 65,757
September 43,471,906 698,149 4,720,860 69,130
October 45,979,056 746,021 4,915,796 71,950
November 48,214,360 776,586 5,060,666 74,152
December 54,859,966 825,816 5,515,250 76,520
January 74,333,528 884,265 8,292,735 79,801
February 79,025,644 949,957 8,961,636 85,043
March 81,780,503 1,007,320 9,102,677 89,052
April 82,658,881 1,018,326 9,192,666 90,145
May 86,065,680 1,032,094 9,574,768 91,591
June 86,967,132 1,015,938 10,024,838 92,113
July 90,733,888 1,027,886 10,367,437 92,784
August 94,199,489 1,043,864 11,052,866 94,959
September 96,067,772 1,506,416 11,233,276 95,796
October 97,450,859 1,070,266 11,363,979 96,892
November 98,568,849 1,079,197 11,492,488 97,437
UPDATED WEEKLY - Last updated on 27 November 2022, 4:15 pm PST, John Hopkins Corona Virus Dashboard and Worldometer
John Hopkins Worldometer
Recovered - Recovered - 624,613,202
POPULATION - is 334,805,269 as of 27 November 2022, 4:15 pm PST, based on Census U.S. and World Population Clock.
Cases in the U.S.
Recovered - Recovered - 97,992,073
*Unemployment increases to 3.7%
*306,000 jobs added in October.
Cases in California
Recovered - Recovered - 11,219,783
*California unemployment rate was 3.9%
11/27/2022 Cases (WHO) Deaths (WHO) Recovered (WHO)
* Rated last in vaccine distribution at 52%, fully vaccinated
*** no updated information at this reporting
United States progress Updated 27 November 2022, 4:15 pm PST,
** No updated information at this reporting
Respiratory Syncytial Virus (RSV) in Children. What is respiratory syncytial virus (RSV) in children? RSV is a viral illness causing symptoms such as trouble breathing. It’s the most common cause of inflammation of the small airways in the lungs, bronchiolitis, and pneumonia in babies. RSV is spread when a child comes into contact with fluid from an infected person’s nose or mouth, such as a contaminated surface, then touching their eyes, mouth, or nose. Or it may occur by inhaling droplets from an infected person’s sneeze or cough. Children are more at risk for RSV when around others with the virus and in yearly outbreaks in communities, classrooms and childcare centers, but more common in winter and early spring months.
Which children are at risk for RSV? RSV can affect any age group but causes the most problems for the very young and very old. Most babies are infected at least once by the time they are 2 years old and can be re-infected with the virus anytime throughout life. RSV infection in older children and adults may present like an episode of severe asthma. Babies born prematurely or with heart, lung, or immune system diseases are at increased risk for more severe illness.
What are the symptoms of RSV in a child? Symptoms start about 2 to 5 days after contact with the virus. Early phases of RSV in babies and young children, is often mild like a cold. In children younger than age 3, RSV may move into the lungs and cause coughing and wheezing and in some children, the infection turns to a severe respiratory disease requiring treatment in a hospital to assist breathing. RSV symptoms can seem like other health conditions. Consult your healthcare provider regarding risks, benefits and possible side effects of all treatments.
The most common symptoms of RSV include:
How is RSV treated in a child? Treatment will depend on your child’s symptoms, age, and general health. Antibiotics are not used to treat RSV. Treatment for RSV helps ease symptoms and may include:
RSV in children: Symptoms, treatment and what parents should know. Updated 5:29 PM EDT, Fri October 28, 2022. For many, RSV causes a mild illness that can be managed at home. On average, an infection lasts five days to a couple of weeks and it will often go away on its own, says the CDC. Sometimes, the cough can linger for up to four weeks, pediatricians say.
They’ve done it again!!!! T R A N S F O R M E D!!! The next U.S. COVID wave is coming. Why it will be 'much weirder than before.' Thurs.,October 13, 2022 at 1:00 PM. First variants were named after Greek letters, like Omicron. Then came BA.5. Now there is BA.2.75.2, BA.4.6, BF.7 and BQ.1.1. There’s an even newer transformer - XBB.
Scientists are seeing Omicron descendants arising simultaneously but advantageous mutations that help them dodge existing immune defenses are driving new waves of infection. Of all 300 post-BA.5 sub-lineages currently being monitored by the World Health Organization — a group that includes BA.4.6, BF.7 and BA.2.75, which have risen as a proportion of U.S. cases in recent weeks.
Experts are most concerned about two Omicron spinoffs that have barely even registered in America yet: BQ.1.1 and XBB. Why? Because they’re “escape” variants! Earlier sub-lineages had a few advantageous mutations – XBB, B.Q.1.1 and now including BN.1 and BA.2.75.2 — boasting at least six changes in the right places on the virus’s spike protein. Some researchers have referred to them as the “pentagon” or “hexagon” variants, ranking as the "most antibody-evasive” strains ever tested, according to Yunlong Richard Cao, an immunologist at Peking University in Beijing.
First, the most vulnerable, the immunocompromised and the elderly, do not produce lasting or strong antibody response after infection or vaccination. Monoclonal antibody treatments have helped shield them from severe illness. Many of these treatments were abandoned after previous variants rendered them useless. Recent lab experiments have shown that remaining antibody therapies, bebtelovimab and Evusheld, don’t work against XBB and B.Q.1.1.
Second is increased spread. Dr. Cao’s experiments show that XBB is “significantly more immune evasive against plasma from all breakthrough infections,” including recent BA.5 infections. The more the virus circulates the more chances it has to reach people who could get seriously ill. Less than 5% of eligible Americans have received the updated bivalent BA.5 shot.
In the United Kingdom, BQ.1.1 infections are doubling every week, a growth rate that exceeds other leading sub-lineages. Germany, France and Belgium are experiencing similarly rapid B.Q.1.1 growth. From Italy to Austria to Sweden, COVID hospitalizations are rising as the weather cools. Meanwhile, XBB is driving steep COVID case surges in Singapore and Bangladesh, two of the first countries where it has achieved dominance.
BQ.1.1 is a descendant of BA.5; XBB a descendent of BA.2. By further broadening immunity, the new bivalent boosters are the best defense. 93% of U.S. seniors have received their first two vaccine doses and only 45% have received their two recommended booster shots, with the number for bivalent boosters much lower. CDC data has shown that vaccine protection against COVID hospitalization fell from 80% to roughly 60% during the various Omicron waves. Without boosters — and with more evasive variants — it’s likely to slip further. Three years in, the virus still has tricks up its sleeve! Will Pi, another radically new variant like Omicron?
What Is BF.7? New COVID Sub-variant Spreading In US. The Centers for Disease Control and Prevention is currently monitoring another COVID variant, as the U.S. heads into another wave of the virus this fall. The BF.7 sub-variant, also known as BA.188.8.131.52, is a sub-lineage of the BA.5 strain of the virus and has grown in other regions of the world. BF.7 has the potential to be more transmissible than BA.5. Not much is known about the BF.7 sub-variant such as its severity and response to the latest Omicron vaccines. BF.7 may not be the only sub-variant seen this year.
The BF.7 sub-variant comprises 1.7% of new COVID cases, finding its way on the CDC's watch list and nearing the number of cases of the BA.4 sub-variant, at 1.8%. The majority of COVID cases in the country is still the BA.5 sub-variant at 84.8% and BA.4.6 at 10.3%, according to the CDC.
25% of the BF.7 cases worldwide have been in Belgium, with Denmark, Germany and France seeing 10% of cases. Dr. Stuart Ray, vice chair of medicine for data integrity and analytics at Johns Hopkins Department of Medicine, its "reasonable to think BF.7 is gaining a foothold."
CDC starts tracking BF.7: 5 notes on the sub-variant. The CDC recently started tracking BF.7, the third most-prevalent strain in the U.S. Things to know:
Preparing for the BF-7 COVID-19 variant and flu season. SEPTEMBER 29, 2022. Alpha, Beta, Gamma, Delta, Omicron, BA-4, BA-5, and now comes BF-7. Each variant brings new challenges and BF-7 has changes that may make it evasive to immunity, meaning if you’ve had Omicron, you may be susceptible to BF-7.
When it comes to vaccines and their effectiveness against BF-7, evidence points to the fact it should do the same for the new variant, especially if you have the BA-5 booster. As a country "our immunity to the flu is dramatically lower than what it usually is. As far as protecting yourself against the latest cold bug, it's the same old handwashing and distancing from folks hacking and sneezing.
FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld. Update 10/3/2022. The FDA added important information to the Fact Sheets for Evusheld, tixagevimab co-packaged with cilgavimab, to inform health care providers and individuals receiving Evusheld of the increased risk for developing COVID-19 when exposed to variants of SARS-CoV-2 that are not neutralized by Evusheld.
Fact Sheet for Healthcare Providers - Health care professionals should inform patients of the risk and advise patients who develop signs or symptoms of COVID-19 to test for SARS-CoV-2 and promptly seek medical attention, including starting treatment for COVID-19.
Evusheld, currently the only option for pre-exposure prophylaxis or PrEP of COVID-19 authorized under Emergency Use Authorization, EUA, for use in immunocompromised individuals and individuals who the COVID-19 vaccination is not recommended due to severe adverse reaction. It is authorized to be administered every six months. Evusheld is not a substitute for COVID-19 vaccination.
The FDA continues to recommend Evusheld as an option for PrEP to prevent COVID-19, in combination with getting vaccinated and boosted. Evusheld offers protection against many of the currently variants and may offer protection against future variants.
What You Should Know:
What Health Care Providers Should Know. There are several treatments that are authorized or approved to treat certain patients with mild-to-moderate COVID-19 who are high risk for progression to severe disease, including hospitalization or death.
How to Protect Yourself? Getting vaccinated is your best bet!
IT’S NOT OVER!
Stay safe. Mask. Social distance. Frequent hand washing. Avoid crowds
ALWAYS CONSULT YOUR PERSONAL HEALTH CARE PROFESSIONAL
1756 N. Riverside Ave
Rialto, CA 92376
Phone: 909 879-1059
Fax : 909 879-1043
Monday 10 am - 4:00 pm Tuesday 10 am - 4:00 pm
Wednesday 10 am - 4:00 pm
Thursday 10 am - 4:00 pm
Friday 10 am - 4:00 pm
HOLIDAY HOURS MAY VARY
10:30 am - 3 pm
Phone orders are encouraged. Large orders prior to 10:30 am
Deliveries not available during covid restrictions.
Stop in to check out all the items currently discounted for your personal resolutions.